BIBR-1048 (Dabigatran etexilate) is an orally-active, non-covalent, reversible inhibitor of thrombin. It is the double ester prodrug of BIBR-953, which has an IC50 against thrombin and trypsin at 9.3, and 50.3 nM, respectively. (1) In addition to inhibiting free thrombin, BIBR-1048 also inhibits thrombin generation, fibrin-bound thrombin, and thrombin-induced platelet aggregation. (2)
Technical information:
| Chemical Formula: | C34H41N7O5 | |
| CAS #: | 211915-06-9 | |
| Molecular Weight: | 627.73 | |
| Purity: | > 98% | |
| Appearance: | white | |
| Chemical Name: | (E)-ethyl 3-(2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | |
| Solubility: | Up to 100 mM in DMSO | |
| Synonyms: | BIBR 1048, BIBR1048, BIBR-1048, Dabigatran, Pradaxa |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Abbenante et al., Protease Inhibitors in the Clinic, Med. Chem. 2005, 1, 71-104. Pubmed ID: 16789888 |
| 2. | Jackson, J.M., Drug Review - Dabigatran for stroke prevention in atrial fibrillation, Drugs in Context, 2011, 6, 11-28. |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
